Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 6/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PRF1 | P14222 | 1/20 | 0.33 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16882582 | 1.00 | TTK (0.45) | TTKEGLN2GLAIDO1ALOX5AP | |
| SCHEMBL6113424 | 0.89 | IKBKB (0.42) | TTKEGLN2GLAIDO1ALOX5AP | |
| SCHEMBL13077304 | 0.88 | TTK (0.47) | TTKBRD4PRF1 | |
| SCHEMBL121661 | 0.87 | TTK (0.41) | TTKGLAIDO1BRD4 | |
| SCHEMBL3804195 | 0.87 | TTK (0.46) | TTKEGLN2IDO1CETPBRD4 | |
| SCHEMBL175741 | 0.85 | CYP1A2 (0.42) | TTKEGLN2IDO1BRD4MOK | |
| SCHEMBL13077242 | 0.83 | TTK (0.47) | TTKBRD4 | |
| SCHEMBL120707 | 0.83 | TTK (0.47) | TTKBRD4 | |
| SCHEMBL122041 | 0.82 | NAMPT (0.43) | TTK | |
| SCHEMBL6113293 | 0.82 | CLK4 (0.40) | TTKGLAIDO1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | claimed |
| EP-2424537-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | Bayer Pharma Aktiengesellschaft (DE) | 2012-03-07 | — | — | EP | claimed |
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | TTBK1, TTK, TTBK2 | TTK 2/4885EGLN2 4319/4885GLA 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.